Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc. (NYSE:TDOC), filed a Form 4 on September 3, 2026, reporting share acquisitions from vesting restricted stock units and performance stock units on September 1, 2026, and a sale of shares on September 2, 2026, to cover tax withholding obligations.

Key Highlights

  • RSU vesting (March 2024 grant): 5,350 shares of common stock acquired on September 1, 2026, via conversion of restricted stock units at $0 exercise price.
  • RSU vesting (March 2025 grant): 9,152 shares of common stock acquired on September 1, 2026, via conversion of restricted stock units at $0 exercise price.
  • PSU vesting: 426 shares of common stock acquired on September 1, 2026, via conversion of performance stock units at $0 exercise price.
  • Tax-withholding sale: 7,573 shares sold on September 2, 2026, at $6.301 per share to cover tax withholding on the vesting awards.
  • Resulting ownership: Following all reported transactions, Vandervoort directly held 117,616 shares of common stock.
  • Remaining derivative securities: 10,700 restricted stock units and 54,918 restricted stock units and 2,553 performance stock units remained beneficially owned after the transactions.

Transaction Details: Vandervoort's RSU and PSU Activity at Teladoc Health

According to the filing, the acquisitions on September 1, 2026, resulted from the vesting of awards under three separate grants. The first involved 5,350 restricted stock units originally granted on March 19, 2024, as part of a 64,200-unit award vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning June 1, 2025. The second involved 9,152 restricted stock units from a March 1, 2025, grant of 109,832 units, vesting one-third on March 1, 2026, with the remainder in eight substantially equal quarterly installments thereafter.

The third acquisition covered 426 performance stock units earned on March 1, 2026, from a total of 5,107 units, also vesting one-third on March 1, 2026, with the remainder in eight substantially equal quarterly installments thereafter. The filing notes that both restricted stock units and performance stock units convert to shares of TDOC common stock on a one-for-one basis.

On September 2, 2026, the filing reports that Vandervoort sold 7,573 shares at $6.301 per share. The filing states these shares were "sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards." After all reported transactions, his direct beneficial ownership stood at 117,616 shares of common stock, according to the filing.

What Was Disclosed

The Form 4 discloses RSU and PSU vestings totaling 14,928 shares acquired by Teladoc Health's Chief Legal Officer on September 1, 2026, followed by a tax-withholding sale of 7,573 shares at $6.301 on September 2, 2026, leaving him with 117,616 shares directly held.